<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993057</url>
  </required_header>
  <id_info>
    <org_study_id>STU00009023</org_study_id>
    <nct_id>NCT00993057</nct_id>
  </id_info>
  <brief_title>Efficiency of Two Glucose Sampling Protocols for Maintenance of Euglycemia</brief_title>
  <official_title>Comparing Two Glucose Sampling Frequencies for an Intensive Insulin Protocol During Craniotomy in Non-Diabetic Patients—How Efficiently and Safely Can We Maintain Target Glucose Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      What is the efficacy and safety of q 30 minutes vs. q 1hour glucose sampling and intervention
      for an intensive insulin protocol to achieve and maintain euglycemia in non-diabetic patients
      undergoing craniotomy? The investigators hypothesize that in non-diabetic patients undergoing
      craniotomy, monitoring glucose and modifying insulin infusions every 30 minutes compared to
      every hour will help them reach target glucose levels faster and maintain them more
      efficiently with the same insulin protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intraoperative blood glucose levels will be maintained in the target range of 90—110 mg/dL
      (euglycemia) using the protocol. The target serum glucose ranges chosen (90-110 mg/dL) was
      chosen to specifically target those levels associated with the best outcome in cerebral
      aneurysm surgery (serum glucose &lt; 108 mg/dL) and aggressively avoid those levels associated
      with cognitive dysfunction (serum glucose &lt; 128 mg/dL) and gross neurologic deficits (serum
      glucose &lt; 152 mg/dL). Because the strength of these data, the investigators utilize an
      aggressive insulin protocol in their routine clinical care of patients undergoing
      craniotomies.

      Each patient will be randomly assigned to one of two frequency of intervention groups—Group
      30 will have the insulin dose adjusted every 30 minutes and Group 60 will have the insulin
      dose adjusted every 60 minutes. Blood glucose levels, insulin boluses and infusion rates, and
      dextrose boluses will be recorded on the respective Intraoperative Insulin &amp; Glucose data
      sheet (Appendix 2 and 3 for Group 30 and Group 60, respectively).

      Regardless of the protocol, glucose measurements will be conducted every 15 minutes but
      insulin intervention will be done at 30 minutes or one hour (per assigned treatment group).
      The interval data (15 minutes for the 30 min group and 15, 30, and 45 minutes for the 1 hour
      group) will be utilized to determine the pharmacodynamic effects of insulin (dose-response
      relationship). Interventions will only be performed at the assigned interval (30 vs 60 min)
      unless the glucose level is &lt; 70 mg/dL, at which time the patient will receive 25 mL of 50%
      Dextrose solution. For these rescued patients, the protocol will be continued as scheduled.

      On the day of surgery, after confirming entry into the study (i.e., confirmation of research
      consent), each patient will be randomly assigned to a specific protocol—q 30 minutes glucose
      measurements and intervention vs. q 60 minutes glucose measurements and
      intervention.Randomization will be performed in blocks of 10 using a computer generated
      random number assignment (odd numbers = q 30 minutes and even numbers = q 60 minutes)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>performance of each of glucose sampling and insulin protocols for achieving euglycemia</measure>
    <time_frame>duration of operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hypoglycemia</measure>
    <time_frame>duration of operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time required to reach euglycemia</measure>
    <time_frame>durarion of operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relationship of BMI and performance of protocols</measure>
    <time_frame>duration of operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relationship of serum biomarkers of insulin resistance and performance of protocols</measure>
    <time_frame>duration of operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Brain Neoplasms</condition>
  <condition>Intracranial Aneurysm</condition>
  <arm_group>
    <arm_group_label>Q1 hour protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>change of insulin infusion every hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Q30min protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>change of insulin infusion every 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Adjustable insulin infusion scale with loading doses</description>
    <arm_group_label>Q1 hour protocol</arm_group_label>
    <arm_group_label>Q30min protocol</arm_group_label>
    <other_name>Humulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All English speaking, non-diabetic, non-pregnant patients over the age of 18
             undergoing open craniotomy for the surgical treatment of tumors or intracranial
             aneurysms.

        Exclusion Criteria:

          -  Patients under 18 years of age, patients who are pregnant, patients with diabetes, BMI
             &gt; 33 kg/m2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dhanesh Gupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University Feinberg School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dhanesh Gupta</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fukuda S, Warner DS. Cerebral protection. Br J Anaesth. 2007 Jul;99(1):10-7. Review.</citation>
    <PMID>17573393</PMID>
  </reference>
  <reference>
    <citation>Lukins MB, Manninen PH. Hyperglycemia in patients administered dexamethasone for craniotomy. Anesth Analg. 2005 Apr;100(4):1129-33.</citation>
    <PMID>15781533</PMID>
  </reference>
  <reference>
    <citation>Lindsberg PJ, Roine RO. Hyperglycemia in acute stroke. Stroke. 2004 Feb;35(2):363-4.</citation>
    <PMID>14757880</PMID>
  </reference>
  <reference>
    <citation>Pasternak JJ, McGregor DG, Schroeder DR, Lanier WL, Shi Q, Hindman BJ, Clarke WR, Torner JC, Weeks JB, Todd MM; IHAST Investigators. Hyperglycemia in patients undergoing cerebral aneurysm surgery: its association with long-term gross neurologic and neuropsychological function. Mayo Clin Proc. 2008 Apr;83(4):406-17. doi: 10.4065/83.4.406.</citation>
    <PMID>18380986</PMID>
  </reference>
  <reference>
    <citation>Carvalho G, Moore A, Qizilbash B, Lachapelle K, Schricker T. Maintenance of normoglycemia during cardiac surgery. Anesth Analg. 2004 Aug;99(2):319-24, table of contents.</citation>
    <PMID>15271698</PMID>
  </reference>
  <reference>
    <citation>Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem. 2006;13(17):1971-8. Review.</citation>
    <PMID>16842191</PMID>
  </reference>
  <reference>
    <citation>Meng YX, Ford ES, Li C, Quarshie A, Al-Mahmoud AM, Giles W, Gibbons GH, Strayhorn G. Association of C-reactive protein with surrogate measures of insulin resistance among nondiabetic US from National Health and Nutrition Examination Survey 1999-2002. Clin Chem. 2007 Dec;53(12):2152-9. Epub 2007 Oct 19.</citation>
    <PMID>17951292</PMID>
  </reference>
  <reference>
    <citation>Olufadi R, Byrne CD. Clinical and laboratory diagnosis of the metabolic syndrome. J Clin Pathol. 2008 Jun;61(6):697-706. doi: 10.1136/jcp.2007.048363. Review.</citation>
    <PMID>18505888</PMID>
  </reference>
  <reference>
    <citation>Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001 Aug;7(8):941-6.</citation>
    <PMID>11479627</PMID>
  </reference>
  <reference>
    <citation>Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):972-8.</citation>
    <PMID>10195925</PMID>
  </reference>
  <reference>
    <citation>Varvel JR, Donoho DL, Shafer SL. Measuring the predictive performance of computer-controlled infusion pumps. J Pharmacokinet Biopharm. 1992 Feb;20(1):63-94.</citation>
    <PMID>1588504</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>John Bebawy</investigator_full_name>
    <investigator_title>Assistant Professor in Anesthesiology and Neurological Surgery</investigator_title>
  </responsible_party>
  <keyword>Euglycemia</keyword>
  <keyword>craniotomy</keyword>
  <keyword>neurosurgery</keyword>
  <keyword>hypoglycemia</keyword>
  <keyword>insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

